Accès libre

A population-based study of the effectiveness of stereotactic ablative radiotherapy versus conventional fractionated radiotherapy for clinical stage I non-small cell lung cancer patients

Chih-Yen Tu
Chih-Yen Tu
, 
Te-Chun Hsia
Te-Chun Hsia
, 
Hsin-Yuan Fang
Hsin-Yuan Fang
, 
Ji-An Liang
Ji-An Liang
, 
Su-Tso Yang
Su-Tso Yang
, 
Chia-Chin Li
Chia-Chin Li
 et 
Chun-Ru Chien
Chun-Ru Chien
   | 07 déc. 2017
Radiology and Oncology's Cover Image
À propos de cet article
Article précédent
Article suivant
Citez
Article Category: Research Article
Publié en ligne: 07 déc. 2017
Pages: 181 - 188
Reçu: 28 juil. 2017
Accepté: 18 sept. 2017
DOI: https://doi.org/10.1515/raon-2017-0058
© 2017 Chih-Yen Tu, Te-Chun Hsia, Hsin-Yuan Fang, Ji-An Liang, Su-Tso Yang, Chia-Chin Li, Chun-Ru Chien, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Figure 1

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) study flowchart and the number of individuals at each stage of the study. 1 We only included those treated (class 1–2) at a single institution to ensure data consistency. 2 Sixth (2007–2009) or Seventh (2010–2013) American Joint Committee on Cancer. 3 60–70 Gy in 1.8–2 Gy/fraction, ±10% in dose. 4 Dose/fraction compatible with National Comprehensive Cancer Network non-small cell lung cancer guideline 2017 v8 (i.e., 25–34 Gy/1 fraction, or 45–60 Gy/3 fractions, or 48–50 Gy/4 fractions, or 50–55 Gy/5 fractions, or 60–70 Gy/8–10 fractions), ±10% in dose. 5Adenocarcinoma or non-adenocarcinoma. 6 Without missing information in the Taiwan cancer registry and death registry.
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) study flowchart and the number of individuals at each stage of the study. 1 We only included those treated (class 1–2) at a single institution to ensure data consistency. 2 Sixth (2007–2009) or Seventh (2010–2013) American Joint Committee on Cancer. 3 60–70 Gy in 1.8–2 Gy/fraction, ±10% in dose. 4 Dose/fraction compatible with National Comprehensive Cancer Network non-small cell lung cancer guideline 2017 v8 (i.e., 25–34 Gy/1 fraction, or 45–60 Gy/3 fractions, or 48–50 Gy/4 fractions, or 50–55 Gy/5 fractions, or 60–70 Gy/8–10 fractions), ±10% in dose. 5Adenocarcinoma or non-adenocarcinoma. 6 Without missing information in the Taiwan cancer registry and death registry.

Figure 2

Kaplan-Meier survival curve for the whole study population. CFRT = conventional fractionated radiotherapy; SABRT = stereotactic ablative radiotherapy
Kaplan-Meier survival curve for the whole study population. CFRT = conventional fractionated radiotherapy; SABRT = stereotactic ablative radiotherapy

Figure 3

Kaplan-Meier survival curve for the first supplementary analysis. CFRT = conventional fractionated radiotherapy; SABRT = stereotactic ablative radiotherapy
Kaplan-Meier survival curve for the first supplementary analysis. CFRT = conventional fractionated radiotherapy; SABRT = stereotactic ablative radiotherapy

Figure 4

Kaplan-Meier survival curve for the second supplementary analysis. CFRT = conventional fractionated radiotherapy; SABRT = stereotactic ablative radiotherapy
Kaplan-Meier survival curve for the second supplementary analysis. CFRT = conventional fractionated radiotherapy; SABRT = stereotactic ablative radiotherapy

Patient characteristics in the second supplementary analysis

SABR CFRT Standardized difference (rounded)

rounded at the second
Number or mean (sd)

rounded at the second

 (%)

rounded at the second

 Number or mean (sd)

rounded at the second

 (%)

rounded at the second
Age 76.92 (8.84) 77.73 (9.19) 0.09
Sex Female 8 (31) 7 (27) 0.09
Male 18 (69) 19 (73)
Residency Non-north 16 (62) 18 (69) 0.16
North 10 (38) 8 (31)
Comorbidity Without # # 0.13
With

modified Carlson comorbidity score ≥ 1

 # #
Histology Adenocarcinoma 14 (54) 15 (58) 0.08
Non-adenocarcinoma 12 (46) 11 (42)
T stage T1 11 (42) 11 (42) 0.00
T2 15 (58) 15 (58)
Use of PET Yes 13 (50) 12 (46) 0.08
No 13 (50) 14 (54)
Use of systemic therapy Yes # # 0.13
No # #
Previous cancer Yes 3 (12) 3 (12) 0.00
No 23 (88) 23 (88)
Performance status ECOG (0–2) # # 0.00
ECOG (3–4) # #

Patient characteristics for the whole study population

SABR CFRT Standardized difference (rounded)

rounded at the second
Number or mean (sd)

rounded at the second

 (%)

rounded at the second

 Number or mean (sd)

rounded at the second

 (%)

rounded at the second

 Before IPW After
Age 77.81 (7.85) 75.40 (9.96) 0.27 0.24
Sex Female 20 (29) 44 (26) 0.07 0.07
Male 49 (71) 125 (74)
Residency Non-north 32 (46) 93 (55) 0.17 0.19
North 37 (54) 76 (45)
Comorbidity Without 9 (13) 43 (25) 0.32 0.25
With

modified Carlson comorbidity score ≥ 1

 60 (87) 126 (75)
Histology Adenocarcinoma 40 (58) 82 (49) 0.19 0.24
Non-adenocarcinoma 29 (42) 87 (51)
T stage T1 38 (55) 49 (29) 0.55 0.08
T2 31 (45) 120 (71)
Period 2007–2009 15 (22) 65 (38) 0.37 0.22
2010–2013 54 (78) 104 (62)
Use of PET Yes 37 (54) 55 (33) 0.44 0.09
No 32 (46) 114 (67)
Use of systemic therapy Yes 10 (14) 73 (43) 0.67 0.17
No 59 (86) 96 (57)
Previous cancer Yes 9 (13) 16 (9) 0.11 0.06
No 60 (87) 153 (91)

Patient characteristics in the first supplementary analysis

SABR CFRT
Standardized difference (rounded)

rounded at the second
Number or mean (sd)

rounded at the second

 (%)

rounded at the second

 Number or mean (sd)

rounded at the second

 (%)

rounded at the second
Age 77.47 (8.26) 77.75 (9.79) 0.03
Sex Female 18 (30) 24 (40) 0.21
Male 42 (70) 36 (60)
Residency Non-north 29 (48) 30 (50) 0.03
North 31 (52) 30 (50)
Comorbidity Without 9 (15) 8 (13) 0.05
With

modified Carlson comorbidity score ≥ 1

 51 (85) 52 (87)
Histology Adenocarcinoma 37 (62) 41 (68) 0.14
Non-adenocarcinoma 23 (38) 19 (32)
T stage T1 30 (50) 31 (52) 0.03
T2 30 (50) 29 (48)
Period 2007–2009 15 (25) 15 (25) 0.00
2010–2013 45 (75) 45 (75)
Use of PET Yes 30 (50) 31 (52) 0.03
No 30 (50) 29 (48)
Use of systemic therapy Yes 10 (17) 13 (22) 0.13
No 50 (83) 47 (78)
Previous cancer Yes 8 (13) 7 (12) 0.05
No 52 (87) 53 (88)
eISSN:
1581-3207
Langue:
Anglais
Périodicité:
4 fois par an
Sujets de la revue:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology
RSS Feed de la revue